|10.99||+0.0700||+0.64%||Vol 2.15M||1Y Perf 7.85%|
|Jan 21st, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||12.33||Analyst Rating||Moderate Buy 2.33|
|Potential %||12.19||Finscreener Ranking||★★★★ 52.20|
|Insiders Trans % 3/6/12 mo.||-100/-100/-39||Value Ranking||★★★★★ 62.65|
|Insiders Value % 3/6/12 mo.||-100/-100/67||Growth Ranking||★★★★★ 68.54|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/70||Income Ranking||— -|
|Price Range Ratio 52W %||40.26||Earnings Rating||Sell|
|Market Cap||1.80B||Earnings Date||16th Feb 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||16th Feb 2022|
|Estimated EPS Next Report||0.31|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||3.19M|
|Avg. Monthly Volume||2.05M|
|Avg. Quarterly Volume||2.18M|
Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) stock closed at 10.99 per share at the end of the most recent trading day (a 0.64% change compared to the prior day closing price) with a volume of 2.17M shares and market capitalization of 1.80B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 232 people. Ironwood Pharmaceuticals Inc. CEO is Mark Mallon.
The one-year performance of Ironwood Pharmaceuticals Inc. stock is 7.85%, while year-to-date (YTD) performance is -5.75%. IRWD stock has a five-year performance of -25.59%. Its 52-week range is between 8.78 and 14.27, which gives IRWD stock a 52-week price range ratio of 40.26%
Ironwood Pharmaceuticals Inc. currently has a PE ratio of 3.60, a price-to-book (PB) ratio of 3.31, a price-to-sale (PS) ratio of 6.47, a price to cashflow ratio of 7.70, a PEG ratio of 2.32, a ROA of 67.75%, a ROC of 72.87% and a ROE of 181.05%. The company’s profit margin is 39.18%, its EBITDA margin is 55.90%, and its revenue ttm is $296.62 Million , which makes it $1.81 revenue per share.
Of the last four earnings reports from Ironwood Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.31 for the next earnings report. Ironwood Pharmaceuticals Inc.’s next earnings report date is 16th Feb 2022.
The consensus rating of Wall Street analysts for Ironwood Pharmaceuticals Inc. is Moderate Buy (2.33), with a target price of $12.33, which is +12.19% compared to the current price. The earnings rating for Ironwood Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Ironwood Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Ironwood Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.82, ATR14 : 0.44, CCI20 : -177.79, Chaikin Money Flow : -0.31, MACD : -0.14, Money Flow Index : 28.62, ROC : -6.31, RSI : 41.55, STOCH (14,3) : 13.85, STOCH RSI : 0.19, UO : 33.36, Williams %R : -86.15), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Ironwood Pharmaceuticals Inc. in the last 12-months were: Alexander J. Denner (Buy at a value of $10 094 250), Edward P. Owens (Buy at a value of $110 370), Jason Rickard (Sold 45 389 shares of value $519 142 ), Julie H. McHugh (Sold 10 000 shares of value $110 200 ), Michael Shetzline (Sold 17 930 shares of value $210 413 ), Ronald Silver (Sold 2 029 shares of value $24 573 ), Thomas A. McCourt (Sold 102 403 shares of value $1 180 251 )
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.